Prevalence of Mutations in the
Plasmodium falciparum
antimalarial drug
in vitro
malaria
molecular marker
pfcoronin
resistance
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
17 Aug 2021
17 Aug 2021
Historique:
received:
20
07
2021
revised:
10
08
2021
accepted:
15
08
2021
entrez:
28
8
2021
pubmed:
29
8
2021
medline:
29
8
2021
Statut:
epublish
Résumé
Artemisinin-based combination therapy (ACT) was recommended to treat uncomplicated falciparum malaria. Unlike the situation in Asia where resistance to ACT has been reported, artemisinin resistance has not yet emerged in Africa. However, some rare failures with ACT or patients continuing to be parasitaemic on day 3 after ACT treatment have been reported in Africa or in travellers returning from Africa. Three mutations (G50E, R100K, and E107V) in the The aims of this study were first to determine the prevalence of mutations in the The three mutations in the The 76S mutation is present in many African countries with a prevalence above 10%. It is reassuring that this mutation does not confer in vitro resistance to ACT partners.
Sections du résumé
BACKGROUND
BACKGROUND
Artemisinin-based combination therapy (ACT) was recommended to treat uncomplicated falciparum malaria. Unlike the situation in Asia where resistance to ACT has been reported, artemisinin resistance has not yet emerged in Africa. However, some rare failures with ACT or patients continuing to be parasitaemic on day 3 after ACT treatment have been reported in Africa or in travellers returning from Africa. Three mutations (G50E, R100K, and E107V) in the
METHODS
METHODS
The aims of this study were first to determine the prevalence of mutations in the
RESULTS
RESULTS
The three mutations in the
CONCLUSIONS
CONCLUSIONS
The 76S mutation is present in many African countries with a prevalence above 10%. It is reassuring that this mutation does not confer in vitro resistance to ACT partners.
Identifiants
pubmed: 34452235
pii: pharmaceutics13081273
doi: 10.3390/pharmaceutics13081273
pmc: PMC8400718
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Santé Publique France
ID : CNR Paludisme
Organisme : Délégation Générale pour l'Armement
ID : PDH-2-NRBC-4-4104
Références
Lancet Infect Dis. 2021 Aug;21(8):1120-1128
pubmed: 33864801
Malar J. 2018 Mar 12;17(1):108
pubmed: 29530046
Malar J. 2013 Jan 24;12:34
pubmed: 23347727
Lancet. 2012 May 26;379(9830):1960-6
pubmed: 22484134
Infection. 2018 Dec;46(6):867-870
pubmed: 29980936
Malar J. 2015 Jul 18;14:280
pubmed: 26187846
Pharmaceuticals (Basel). 2021 Apr 09;14(4):
pubmed: 33918981
J Infect Dis. 2021 Jul 03;:
pubmed: 34216470
Sci Rep. 2020 Jun 1;10(1):8907
pubmed: 32483161
N Engl J Med. 2014 Jul 31;371(5):411-23
pubmed: 25075834
Proc Natl Acad Sci U S A. 2019 Jun 25;116(26):12611-12612
pubmed: 31239363
Methods Mol Biol. 2019;2013:29-44
pubmed: 31267491
Malar J. 2011 Sep 18;10:268
pubmed: 21923936
Nat Med. 2020 Oct;26(10):1602-1608
pubmed: 32747827
PLoS Genet. 2020 Dec 28;16(12):e1009266
pubmed: 33370279
Med Mal Infect. 2020 Mar;50(2):99-112
pubmed: 31257063
PLoS Pathog. 2016 Jul 13;12(7):e1005710
pubmed: 27409081
Nature. 2014 Jan 2;505(7481):50-5
pubmed: 24352242
Emerg Infect Dis. 2021 Jan;27(1):294-296
pubmed: 33350925
Malar J. 2016 Nov 3;15(1):525
pubmed: 27809844
Malar J. 2017 Feb 2;16(1):62
pubmed: 28153004
Malar J. 2020 Jun 8;19(1):206
pubmed: 32513171
Malar J. 2015 Feb 05;14:49
pubmed: 25848972
N Engl J Med. 2009 Jul 30;361(5):455-67
pubmed: 19641202
JAMA Netw Open. 2019 Apr 5;2(4):e191691
pubmed: 30951158
Am J Trop Med Hyg. 2016 Nov 2;95(5):1054-1060
pubmed: 27549635
Lancet Infect Dis. 2017 May;17(5):491-497
pubmed: 28161569
Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):12799-12804
pubmed: 30420498
Rev Prat. 2019 Feb;69(2):150-152
pubmed: 30983212
N Engl J Med. 2016 Jun 23;374(25):2453-64
pubmed: 27332904
Antimicrob Agents Chemother. 2017 Feb 23;61(3):
pubmed: 28137810
Malar J. 2019 Aug 23;18(1):285
pubmed: 31443646
Antimicrob Agents Chemother. 2018 Jan 25;62(2):
pubmed: 29229635
Int J Antimicrob Agents. 2017 Jun;49(6):754-756
pubmed: 28450175
Int J Antimicrob Agents. 2020 Dec;56(6):106190
pubmed: 33045351